SrasV1, PascalFrancis, Curation, bibRecord, 000633

Intranasal Protollin-formulated recombinant SARS S-protein elicits respiratory and serum neutralizing antibodies and protection in mice

Identifieur interne : 000633 ( PascalFrancis/Curation ); précédent : 000632; suivant : 000634

Intranasal Protollin-formulated recombinant SARS S-protein elicits respiratory and serum neutralizing antibodies and protection in mice

Auteurs : Mary C. Hu [États-Unis] ; Taff Jones [Canada] ; Richard T. Kenney [États-Unis] ; Dale L. Barnard [États-Unis] ; David S. Burt [Canada] ; George H. Lowell [Canada]

Source :

Vaccine [ 0264-410X ] ; 2007.

RBID : Pascal:07-0388604

Descripteurs français

Pascal (Inist)
- Souris, Voie intranasale, Protéine recombinante, Protéine sérique, Anticorps neutralisant, Vaccin.
Wicri :
- topic : Vaccin.

English descriptors

KwdEn :
- Intranasal administration, Mouse, Neutralizing antibody, Recombinant protein, Serum protein, Vaccine.

Abstract

The feasibility of developing a prophylactic vaccine against SARS was assessed by comparing the immune responses elicited by immunizing mice with a recombinant SARS spike glycoprotein (S-protein) formulated with different adjuvants, given by different routes. In both young and aged mice, an intranasal Protollin-formulated S-protein vaccine elicited high levels of antigen-specific IgG in serum, comparable to those elicited by an intramuscular Alum-adsorbed S-protein vaccine. Serum antibodies were shown to be virus neutralizing. Intranasal immunization of young mice with the Protollin-formulated vaccine elicited significant levels of antigen-specific lung IgA in contrast to mice immunized with the intramuscular vaccine in which no antigen-specific lung IgA was detected. Following live virus challenge of aged mice, no virus was detected in the lungs of intranasally immunized mice, in contrast to intramuscularly immunized mice whose lung virus titers were comparable to those observed in control mice.

A01	`01`	`1`		`@0 0264-410X`
A02	`01`			`@0 VACCDE`
A03		`1`		`@0 Vaccine`
A05				`@2 25`
A06				`@2 34`
A08	`01`	`1`	`ENG`	`@1 Intranasal Protollin-formulated recombinant SARS S-protein elicits respiratory and serum neutralizing antibodies and protection in mice`
A11	`01`	`1`		`@1 HU (Mary C.)`
A11	`02`	`1`		`@1 JONES (Taff)`
A11	`03`	`1`		`@1 KENNEY (Richard T.)`
A11	`04`	`1`		`@1 BARNARD (Dale L.)`
A11	`05`	`1`		`@1 BURT (David S.)`
A11	`06`	`1`		`@1 LOWELL (George H.)`
A14	`01`			`@1 GlaxoSmithKline Biologicals North America of Washington, 19204 North Creek Parkway @2 Bothell, WA 98011 @3 USA @Z 1 aut.`
A14	`02`			`@1 GlaxoSmithKline Biologicals North America of Quebec, 525 Cartier Blvd. West, Laval @2 Montreal, Quebec H7V 3S8 @3 CAN @Z 2 aut. @Z 5 aut. @Z 6 aut.`
A14	`03`			`@1 GlaxoSmithKline Biologicals North America of Maryland, 6996 Columbia Gateway Drive @2 Columbia, MA 21046 @3 USA @Z 3 aut.`
A14	`04`			`@1 Institute for Antiviral Research, Department of ADVS, Utah State University @2 Logan, UT 84322 @3 USA @Z 4 aut.`
A20				`@1 6334-6340`
A21				`@1 2007`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20289 @5 354000146734700080`
A44				`@0 0000 @1 © 2007 INIST-CNRS. All rights reserved.`
A45				`@0 22 ref.`
A47	`01`	`1`		`@0 07-0388604`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Vaccine`
A66	`01`			`@0 GBR`
C01	`01`		`ENG`	@0 The feasibility of developing a prophylactic vaccine against SARS was assessed by comparing the immune responses elicited by immunizing mice with a recombinant SARS spike glycoprotein (S-protein) formulated with different adjuvants, given by different routes. In both young and aged mice, an intranasal Protollin-formulated S-protein vaccine elicited high levels of antigen-specific IgG in serum, comparable to those elicited by an intramuscular Alum-adsorbed S-protein vaccine. Serum antibodies were shown to be virus neutralizing. Intranasal immunization of young mice with the Protollin-formulated vaccine elicited significant levels of antigen-specific lung IgA in contrast to mice immunized with the intramuscular vaccine in which no antigen-specific lung IgA was detected. Following live virus challenge of aged mice, no virus was detected in the lungs of intranasally immunized mice, in contrast to intramuscularly immunized mice whose lung virus titers were comparable to those observed in control mice.
C02	`01`	`X`		`@0 002A05F04`
C03	`01`	`X`	`FRE`	`@0 Souris @5 01`
C03	`01`	`X`	`ENG`	`@0 Mouse @5 01`
C03	`01`	`X`	`SPA`	`@0 Ratón @5 01`
C03	`02`	`X`	`FRE`	`@0 Voie intranasale @5 05`
C03	`02`	`X`	`ENG`	`@0 Intranasal administration @5 05`
C03	`02`	`X`	`SPA`	`@0 Vía intranasal @5 05`
C03	`03`	`X`	`FRE`	`@0 Protéine recombinante @5 06`
C03	`03`	`X`	`ENG`	`@0 Recombinant protein @5 06`
C03	`03`	`X`	`SPA`	`@0 Proteína recombinante @5 06`
C03	`04`	`X`	`FRE`	`@0 Protéine sérique @5 07`
C03	`04`	`X`	`ENG`	`@0 Serum protein @5 07`
C03	`04`	`X`	`SPA`	`@0 Proteína sérica @5 07`
C03	`05`	`X`	`FRE`	`@0 Anticorps neutralisant @5 08`
C03	`05`	`X`	`ENG`	`@0 Neutralizing antibody @5 08`
C03	`05`	`X`	`SPA`	`@0 anticuerpo neutralizante @5 08`
C03	`06`	`X`	`FRE`	`@0 Vaccin @5 09`
C03	`06`	`X`	`ENG`	`@0 Vaccine @5 09`
C03	`06`	`X`	`SPA`	`@0 Vacuna @5 09`
C07	`01`	`X`	`FRE`	`@0 Rodentia @2 NS`
C07	`01`	`X`	`ENG`	`@0 Rodentia @2 NS`
C07	`01`	`X`	`SPA`	`@0 Rodentia @2 NS`
C07	`02`	`X`	`FRE`	`@0 Mammalia @2 NS`
C07	`02`	`X`	`ENG`	`@0 Mammalia @2 NS`
C07	`02`	`X`	`SPA`	`@0 Mammalia @2 NS`
C07	`03`	`X`	`FRE`	`@0 Vertebrata @2 NS`
C07	`03`	`X`	`ENG`	`@0 Vertebrata @2 NS`
C07	`03`	`X`	`SPA`	`@0 Vertebrata @2 NS`
N21				`@1 253`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000356

Links to Exploration step

Pascal:07-0388604

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Intranasal Protollin-formulated recombinant SARS S-protein elicits respiratory and serum neutralizing antibodies and protection in mice</title>
<author><name sortKey="Hu, Mary C" sort="Hu, Mary C" uniqKey="Hu M" first="Mary C." last="Hu">Mary C. Hu</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>GlaxoSmithKline Biologicals North America of Washington, 19204 North Creek Parkway</s1>
<s2>Bothell, WA 98011</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Jones, Taff" sort="Jones, Taff" uniqKey="Jones T" first="Taff" last="Jones">Taff Jones</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>GlaxoSmithKline Biologicals North America of Quebec, 525 Cartier Blvd. West, Laval</s1>
<s2>Montreal, Quebec H7V 3S8</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Kenney, Richard T" sort="Kenney, Richard T" uniqKey="Kenney R" first="Richard T." last="Kenney">Richard T. Kenney</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>GlaxoSmithKline Biologicals North America of Maryland, 6996 Columbia Gateway Drive</s1>
<s2>Columbia, MA 21046</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Barnard, Dale L" sort="Barnard, Dale L" uniqKey="Barnard D" first="Dale L." last="Barnard">Dale L. Barnard</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Institute for Antiviral Research, Department of ADVS, Utah State University</s1>
<s2>Logan, UT 84322</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Burt, David S" sort="Burt, David S" uniqKey="Burt D" first="David S." last="Burt">David S. Burt</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>GlaxoSmithKline Biologicals North America of Quebec, 525 Cartier Blvd. West, Laval</s1>
<s2>Montreal, Quebec H7V 3S8</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Lowell, George H" sort="Lowell, George H" uniqKey="Lowell G" first="George H." last="Lowell">George H. Lowell</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>GlaxoSmithKline Biologicals North America of Quebec, 525 Cartier Blvd. West, Laval</s1>
<s2>Montreal, Quebec H7V 3S8</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">07-0388604</idno>
<date when="2007">2007</date>
<idno type="stanalyst">PASCAL 07-0388604 INIST</idno>
<idno type="RBID">Pascal:07-0388604</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000356</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000633</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Intranasal Protollin-formulated recombinant SARS S-protein elicits respiratory and serum neutralizing antibodies and protection in mice</title>
<author><name sortKey="Hu, Mary C" sort="Hu, Mary C" uniqKey="Hu M" first="Mary C." last="Hu">Mary C. Hu</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>GlaxoSmithKline Biologicals North America of Washington, 19204 North Creek Parkway</s1>
<s2>Bothell, WA 98011</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Jones, Taff" sort="Jones, Taff" uniqKey="Jones T" first="Taff" last="Jones">Taff Jones</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>GlaxoSmithKline Biologicals North America of Quebec, 525 Cartier Blvd. West, Laval</s1>
<s2>Montreal, Quebec H7V 3S8</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Kenney, Richard T" sort="Kenney, Richard T" uniqKey="Kenney R" first="Richard T." last="Kenney">Richard T. Kenney</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>GlaxoSmithKline Biologicals North America of Maryland, 6996 Columbia Gateway Drive</s1>
<s2>Columbia, MA 21046</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Barnard, Dale L" sort="Barnard, Dale L" uniqKey="Barnard D" first="Dale L." last="Barnard">Dale L. Barnard</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Institute for Antiviral Research, Department of ADVS, Utah State University</s1>
<s2>Logan, UT 84322</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Burt, David S" sort="Burt, David S" uniqKey="Burt D" first="David S." last="Burt">David S. Burt</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>GlaxoSmithKline Biologicals North America of Quebec, 525 Cartier Blvd. West, Laval</s1>
<s2>Montreal, Quebec H7V 3S8</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Lowell, George H" sort="Lowell, George H" uniqKey="Lowell G" first="George H." last="Lowell">George H. Lowell</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>GlaxoSmithKline Biologicals North America of Quebec, 525 Cartier Blvd. West, Laval</s1>
<s2>Montreal, Quebec H7V 3S8</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Vaccine</title>
<title level="j" type="abbreviated">Vaccine</title>
<idno type="ISSN">0264-410X</idno>
<imprint><date when="2007">2007</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Vaccine</title>
<title level="j" type="abbreviated">Vaccine</title>
<idno type="ISSN">0264-410X</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Intranasal administration</term>
<term>Mouse</term>
<term>Neutralizing antibody</term>
<term>Recombinant protein</term>
<term>Serum protein</term>
<term>Vaccine</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Souris</term>
<term>Voie intranasale</term>
<term>Protéine recombinante</term>
<term>Protéine sérique</term>
<term>Anticorps neutralisant</term>
<term>Vaccin</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Vaccin</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The feasibility of developing a prophylactic vaccine against SARS was assessed by comparing the immune responses elicited by immunizing mice with a recombinant SARS spike glycoprotein (S-protein) formulated with different adjuvants, given by different routes. In both young and aged mice, an intranasal Protollin-formulated S-protein vaccine elicited high levels of antigen-specific IgG in serum, comparable to those elicited by an intramuscular Alum-adsorbed S-protein vaccine. Serum antibodies were shown to be virus neutralizing. Intranasal immunization of young mice with the Protollin-formulated vaccine elicited significant levels of antigen-specific lung IgA in contrast to mice immunized with the intramuscular vaccine in which no antigen-specific lung IgA was detected. Following live virus challenge of aged mice, no virus was detected in the lungs of intranasally immunized mice, in contrast to intramuscularly immunized mice whose lung virus titers were comparable to those observed in control mice.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0264-410X</s0>
</fA01>
<fA02 i1="01"><s0>VACCDE</s0>
</fA02>
<fA03 i2="1"><s0>Vaccine</s0>
</fA03>
<fA05><s2>25</s2>
</fA05>
<fA06><s2>34</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Intranasal Protollin-formulated recombinant SARS S-protein elicits respiratory and serum neutralizing antibodies and protection in mice</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>HU (Mary C.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>JONES (Taff)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>KENNEY (Richard T.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>BARNARD (Dale L.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>BURT (David S.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>LOWELL (George H.)</s1>
</fA11>
<fA14 i1="01"><s1>GlaxoSmithKline Biologicals North America of Washington, 19204 North Creek Parkway</s1>
<s2>Bothell, WA 98011</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>GlaxoSmithKline Biologicals North America of Quebec, 525 Cartier Blvd. West, Laval</s1>
<s2>Montreal, Quebec H7V 3S8</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>GlaxoSmithKline Biologicals North America of Maryland, 6996 Columbia Gateway Drive</s1>
<s2>Columbia, MA 21046</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Institute for Antiviral Research, Department of ADVS, Utah State University</s1>
<s2>Logan, UT 84322</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA20><s1>6334-6340</s1>
</fA20>
<fA21><s1>2007</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20289</s2>
<s5>354000146734700080</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2007 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>22 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>07-0388604</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Vaccine</s0>
</fA64>
<fA66 i1="01"><s0>GBR</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>The feasibility of developing a prophylactic vaccine against SARS was assessed by comparing the immune responses elicited by immunizing mice with a recombinant SARS spike glycoprotein (S-protein) formulated with different adjuvants, given by different routes. In both young and aged mice, an intranasal Protollin-formulated S-protein vaccine elicited high levels of antigen-specific IgG in serum, comparable to those elicited by an intramuscular Alum-adsorbed S-protein vaccine. Serum antibodies were shown to be virus neutralizing. Intranasal immunization of young mice with the Protollin-formulated vaccine elicited significant levels of antigen-specific lung IgA in contrast to mice immunized with the intramuscular vaccine in which no antigen-specific lung IgA was detected. Following live virus challenge of aged mice, no virus was detected in the lungs of intranasally immunized mice, in contrast to intramuscularly immunized mice whose lung virus titers were comparable to those observed in control mice.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002A05F04</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Souris</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Mouse</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Ratón</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Voie intranasale</s0>
<s5>05</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Intranasal administration</s0>
<s5>05</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Vía intranasal</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Protéine recombinante</s0>
<s5>06</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Recombinant protein</s0>
<s5>06</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Proteína recombinante</s0>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Protéine sérique</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Serum protein</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Proteína sérica</s0>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Anticorps neutralisant</s0>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Neutralizing antibody</s0>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>anticuerpo neutralizante</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Vaccin</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Vaccine</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Vacuna</s0>
<s5>09</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Rodentia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Rodentia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Rodentia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fN21><s1>253</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000633 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000633 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:07-0388604
   |texte=   Intranasal Protollin-formulated recombinant SARS S-protein elicits respiratory and serum neutralizing antibodies and protection in mice
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

Intranasal Protollin-formulated recombinant SARS S-protein elicits respiratory and serum neutralizing antibodies and protection in mice

Intranasal Protollin-formulated recombinant SARS S-protein elicits respiratory and serum neutralizing antibodies and protection in mice

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri